NCT06181513 · Early Phase 1 · RECRUITING
Probiotics in Mild Alzheimer's Disease
This trial is testing whether a daily probiotic capsule can reduce brain inflammation, improve thinking and memory, and change brain activity patterns in people who already have mild Alzheimer's disease. It compares the probiotic group to a placebo group. This is an Early Phase 1 trial, meaning it is a very early-stage safety and feasibility test — far from proven or approved.
You may qualify if
- Adults ≥65 years, able to give consent
- Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)
- approximately equal male:female ratio
You're excluded if
- Inability to give consent
- other neurological disease
- relevant psychiatric disorders (e.g. major depression)
- gastrointestinal/metabolic conditions
- history of alcohol/substance dependence
- use of systemic antibiotics in the previous 6 months
- corticosteroid use
- immune stimulating medications
- immunosuppressive agents
- probiotics consumption in the previous 6 months.
- immunosuppression
- structural heart disease
- neutropenia
- radiation
- active intestinal disease
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-12-05